Researchers have developed a new bacterial immunotherapy that delivers immune-activating proteins directly to solid tumors, which can often suppress the immune system. ACTM-838 targets phagocytic immune cells within the tumor microenvironment.
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.